NCM
JBIO

Nantahala Capital Management’s Jade Biosciences JBIO Stock Holding History

Nantahala Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,798
Closed -$1.28M – 146
2024
Q4 		$1.28M Buy
+13,798
New +$1.19M 0.06% 118
2024
Q2 		– Sell
-2,605
Closed -$2.7M – 133
2024
Q1 		$2.7M Hold
2,605
– – 0.15% 85
2023
Q4 		$2.06M Sell
2,605
-109
-4% -$55.5K 0.12% 87
2023
Q3 		$1.29M Hold
2,714
– – 0.11% 98
2023
Q2 		$1.63M Hold
2,714
– – 0.16% 83
2023
Q1 		$1.92M Buy
2,714
+2,265
+504% +$1.88M 0.15% 76
2022
Q4 		$460K Buy
+449
New +$326K 0.03% 97

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
AI
Allostery Investments Stamford, Connecticut $7.85M AUM
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nantahala Capital Management's JBIO Position: Q1 2025 in Review

Nantahala Capital Management sold out of Jade Biosciences (JBIO) in Q1 2025, closing a stake of 13,798 shares — an estimated $1.28M sold.

Nantahala Capital Management first reported a position in JBIO in Q4 2022 and held it in 7 quarters. The position peaked at $2.7M in Q1 2024. 78 funds tracked by Wall St. Rank hold JBIO as of Q1 2025.

  • Nantahala Capital Management reported no remaining Jade Biosciences position as of Q1 2025 after selling out during the quarter.
  • Nantahala Capital Management sold 13,798 Jade Biosciences shares in Q1 2025, an estimated $1.28M.
  • Nantahala Capital Management first reported a position in Jade Biosciences in Q4 2022 and held it in 7 quarters.
  • Nantahala Capital Management's Jade Biosciences position peaked at $2.7M in Q1 2024.
  • 78 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2025.

Based on Nantahala Capital Management's 13F filing for Q1 2025, filed 15 May 2025.